South Dakota Investment Council Reduces Holdings in Eli Lilly and Company (NYSE:LLY)

South Dakota Investment Council cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,286 shares of the company’s stock after selling 1,900 shares during the quarter. Eli Lilly and Company accounts for about 0.8% of South Dakota Investment Council’s investment portfolio, making the stock its 13th largest holding. South Dakota Investment Council’s holdings in Eli Lilly and Company were worth $38,639,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Lipe & Dalton purchased a new stake in Eli Lilly and Company during the 4th quarter valued at about $26,000. Thompson Investment Management Inc. purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $27,000. Legacy Financial Group LLC purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $35,000. Optiver Holding B.V. purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $36,000. Finally, Family CFO Inc purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $40,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 2.0 %

Shares of LLY stock traded up $14.29 during mid-day trading on Tuesday, hitting $745.62. The company’s stock had a trading volume of 2,041,595 shares, compared to its average volume of 3,051,032. Eli Lilly and Company has a 52-week low of $370.68 and a 52-week high of $800.78. The business has a 50-day moving average price of $763.83 and a 200 day moving average price of $662.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a market cap of $708.46 billion, a price-to-earnings ratio of 127.57, a PEG ratio of 1.58 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the business earned $2.09 earnings per share. The company’s revenue was up 28.1% on a year-over-year basis. Research analysts predict that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Morgan Stanley increased their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday, April 15th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Barclays increased their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Finally, TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.